Intelligence · INN directory
Obesity & Metabolic Drugs
GLP-1, GIP/GLP-1 dual agonists, and metabolic disease therapies including obesity and type 2 diabetes treatments.
Quick answer
Obesity & metabolic drugs: NovaPharmaNews indexes 4 pharmaceutical drugs in this therapeutic segment with regulatory status, pipeline programs, patents, and congress coverage cross-links. GLP-1, GIP/GLP-1 dual agonists, and metabolic disease therapies including obesity and type 2 diabetes treatments.
Recently updated
FDA-approved
-
liraglutide
SAXENDA Teva Pharma GmbH
A10BJ02 -
semaglutide
OZEMPIC NovoThirteen
A10BJ06 -
tirzepatide
MOUNJARO
A10BX16 -
metabolically
Frequently asked questions
How many obesity & metabolic drugs are in the directory?
4 drug profiles match this therapeutic area filter based on class, mechanism, target, and INN metadata.
How are drugs assigned to a therapeutic area?
Classification uses WHO therapeutic class, mechanism of action, molecular target, and INN pattern matching against curated oncology, metabolic, CNS, rare disease, and immunology taxonomies.
Where does regulatory data come from?
Profiles combine FDA Drugs@FDA, EMA EPAR references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence.